Good News : Oxford Publishes COVID-19 Vaccine Trial Results, Claims the Vaccine ‘Safe’ in Medical Journal
London : Oxford University has released the results of the first phase of the trial of the corona vaccine. The vaccine is safe, according to the editor-in-chief of the medical journal Lancet. Scientists at the University of Oxford say their experimental coronavirus vaccine has produced a protective immunological response in the initial trial of hundreds of people who were vaccinated. British researchers first began testing the vaccine in April in about 1,000 people, half of whom were given the experimental vaccine.
Results of phase 1/2 Oxford Covid-19 Vaccine trial published. Editor in Chief of UK based medical Journal ‘The Lancet’ says it is “safe, well-tolerated and immunogenic.” pic.twitter.com/8SyI97Dqgb
— ANI (@ANI) July 20, 2020
Initial tests of this kind are usually performed only to evaluate safety, but in this case, experts were also looking to see what kind of immune response it would have. In research published on Monday in the journal ‘Lancet’, scientists said they found that their experimental COVID-19 vaccine caused a dual immune response in people between 18 and 55 years of age.
“We are seeing a good immune response in almost everyone,” said Dr. Adrian Hill, director of the Jenner Institute at the University of Oxford. “This vaccine would have particularly strengthened both sides of the immune system. Hill said that atoms produced by neutralizing antibodies are important to prevent infection.
In addition, this vaccine causes a reaction in the body’s T-cells that help fight the Coronavirus. He said that large trials evaluating the vaccine’s effectiveness included around 10,000 people from the UK as well as participants from South Africa and Brazil. These trials are still going on in a big way.
Another major trial is due to begin soon in the US, with a target to include around 30,000 people. How quickly scientists are able to determine the effectiveness of a vaccine will largely depend on how much testing there does, but Hill speculates that they may have enough data by the end of the year to make sure whether the vaccine should be adopted for mass vaccination campaigns.
Hill said the Oxford vaccine is designed to reduce the disease and its spread. Hill said Oxford has partnered with pharmaceutical manufacturer AstraZeneca to produce its vaccines globally and the company has already committed to making two billion doses.